Study Group: Mood Disorder Psychiatrists
Council Members in this Study Group: 165
This study group may include physicians, care providers, and researchers specializing in internal medicine, cardiology, oncology, dermatology, emergency medicine, family medicine, neurology, obstetrics-gynecology, psychiatry, radiology, nursing, optometry, genetics, and mental health. It may also include experts knowledgeable on diagnostic labs, disease management, medical devices, long term care, surgery centers, health management, pharma, and biotechnology, among others.
Contact Gerson Lehrman Group to survey or consult with members of this Study Group
Leading institutions connect with members of this Study Group through GLG
Leading Experts in this Study Group
- Robert Schulte
Psychiatrist
North Scottsdale Psychiatric Specialists
Robert Schulte, MD, is a Private Practitioner and a Psychiatrist at North Scottsdale Psychiatric Specialists in Arizona. He is board certified in Adult Psychiatry and Child and Adolescent Psychiatry with extensive experience with children and adult's...
Amit VijapuraOwner
AMIT VIJAPURA MDAmit Vijapura, MD, is a Private Practitioner in Psychiatry based in Florida. He has over 15 years of experience in the field and has expertise in depression, bipolar disorder, anxiety disorder, attention deficient disorder, and schizophrenia. Dr. Vijapura...
GLG NewsSM Analyses by this Study Group's Leading Experts(?)
Opinions and analyses expressed in GLG News are solely those of the author. See the Terms of Use for details.
-
Lilly has great product pipe line for Schizophrenia and other Psychiatric Disorders
September 24, 2007
Analysis by: Amit Vijapura, Owner,Investigational Agent Targeting Metabotropic Glutamate 2/3 Receptors Demonstrates Antipsychotic Activity in Humans, Study in Nature Medicine Finds | www.pipelinereview.com
Lilly is currently leader in Psychiatry with 4 active medications with great marketing for Psychiatry and Primary care physician. New compound that has a unique mechanism on Metabotropic Glutamate 2/3 Receptors, can work on Schizophrenia and other Psychiatric diagnosis. This is great opportunity for Lilly to continue with its leaders ship position in Psychiatry market, which is a fasted growing sector in medical research. LY2140023 is still going thru Phase II trials and its results are not yet released.
-
Quetiapine and Borderline personality disorder
September 1, 2006
Analysis by: Amit Vijapura, Owner,Quetiapine Effective for Borderline Personality Disorder | www.medscape.com
How is Borderline personality disorder treated in Psychiatry practice ?
Use of Quetiapine (Seroquel) in B.P.D. -
ADHD treatment with Stimulant drugs and current FDA warning
August 24, 2006
Analysis by: Amit Vijapura, Owner,UPDATE 2-US FDA calls for new warnings on ADHD drugs | yahoo.reuters.com
Treatment of ADHD is fastest growing market in USA and abroad. New warning by FDA can affect prescription growth and can have major impact on companies like SHIRE who is heavily relying on Stimulant medication use for their profit.
Members in this Study Group include these company types:
- Academic Medical Center/Hospital or Clinic
- Office Based Private Practice or Clinic
- Non-Academic Community Hospital or Clinic
- Academic Institution*
- Government/Military Hospital or Clinic
- Private/For-Profit Healthcare Research Entity
Members in this Study Group often have these job titles:
- Physician - Attending Physician
- Physician - Director
- Owner
- Director
- Physician - Department Chair
- Physician - Division Head
Related Study Groups
| Study Group Name | No. Members |
|---|---|
| Psychiatrists | 1535 |
| Psychiatrists who Treat Mood Disorders (US) | 117 |
| Psychiatrists (US) | 1136 |
| Physicians who Treat Schizophrenia (US) | 364 |
| Physicians who Treat Depression (US) | 448 |
| Psychiatrists who Treat Anxiety Disorders (US) | 93 |
| Physicians who Treat ADHD (US) | 453 |
| Psychiatrists (EU) | 289 |